• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

PolyNovo Share Price Up as Study Results Encourage Market (ASX:PNV)

Like 0

By Carl Wittkopp, Tuesday, 21 April 2020

After an initial fall in line with the COVID-19 influence on the ASX 200 [XJO], the PolyNovo Ltd [ASX:PNV] share price shot up 66.27% from its low to close at $2.12, at the time of writing. PolyNovo is an Australian-based medical device company...

After an initial fall in line with the COVID-19 influence on the ASX 200 [XJO], the PolyNovo Ltd [ASX:PNV] share price shot up 66.27% from its low to close at $2.12, at the time of writing.

PolyNovo is an Australian-based medical device company that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology.

ASX PNV - PolyNovo Share Price Chart 1

Source: Optuma

On 16 March, PolyNovo announced to the ASX that it had:

‘Submitted their Feasibility trial results to US FDA but could not release the results until they had been reviewed by the FDA. These can now publicly release the summary of the results from this BARDA funded burn trial.’

The announcement continued…

‘PolyNovo is pleased to share the summary of results for the CP-002 Feasibility Study to assess the safety and effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the treatment of severe skin burn injuries. This trial was a prospective, multicentre, single-arm, open label, traditional feasibility study conducted in the USA, where NovoSorb® BTM was used under an FDA Investigational Device Exemption (IDE).’

‘The Coronavirus Portfolio’: The two-pronged plan to help you deal with the financial implications of COVID-19. Download your free report here.

The result

The company was clearly enthused, with CEO Mr Paul Brennan stating:

‘These results are outstanding. Not only has NovoSorb BTM integrated well, the take of the split skin grafts and closure of these wounds is remarkable. Burns are often contaminated so seeing infections within this cohort is not unusual.

‘What is unusual is seeing the Matrix continue to integrate and later for the skin graft to take to the matrix with an excellent clinical and cosmetic outcome.

‘The health economics of this success is a strong selling message for us and in the forthcoming Pivotal trial gathering hard health economic data will add to our armoury and success.’

Looking forward, what’s in store for the PNV share price

On 7 April, PolyNovo sales were 166% up in the March quarter versus last year, to go with the encouraging results from its trials in the US.

On the charts, the PolyNovo share price has rocketed up from the low in March of $1.27. Currently hovering around a historical resistance level of $2.17. Should PolyNovo continue its run up, levels of $2.38 and $2.65 may come into focus.

ASX PNV - PolyNovo Share Price Chart 2

Source: Optuma

It’s important to remember that since starting out as a speculative small-cap with a breakthrough product, PolyNovo is now a relative heavyweight.

Listed on the ASX 200, ASX ETFs are obliged to purchase its shares as part of their holdings.

This means that going forward, you may start to see PNV shares move more with the market.

So despite the recent run up the charts, there could be another leg down for the PolyNovo share price before continuing its ascent.

With this in mind, if you’re looking for help dealing with the financial fallout of COVID-19, check out ‘The Coronavirus Portfolio’.

We’ve constructed a two-pronged plan that could help you benefit if the crisis worsens. And help prepare you for the big changes in the world of finance that are to come.

Download your free report here.

Regards,

Carl Wittkopp,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • From geek to God: the trillion dollar maven
    By Callum Newman

    Here’s a few things I discovered this month after reading The Thinking Machine: Jensen Huang, Nvidia, and the World’s Most Coveted Microchip. If you want to be a billionaire, have a read of this!

  • The stock market prices in peace in the Middle East
    By Brian Chu

    Will the conflict between Israel and Iran escalate? Today, I present my views on why it could de-escalate sooner than many are made to believe.

  • Ignore the bores and the bears: some shares are going gangbusters
    By Callum Newman

    All year you and I have been on a mission. It’s to discover if now is the time to be upping your exposure to risk assets, or dialling it down. I put my stake in the ground ages ago: get bullish! It’s working.

Primary Sidebar

Latest Articles

  • From geek to God: the trillion dollar maven
  • The stock market prices in peace in the Middle East
  • Ignore the bores and the bears: some shares are going gangbusters
  • The Perfect Marriage: Combining Fundamental AND Technical Analysis
  • Your best chance to be in the top 10% will come from here

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988